Celebrity Inventors
Penn Jillette of Penn and Teller fame has patented a "Hydro-Therapeutic Stimulator", which uses a hot tub for stimulation.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7268110 | Agents for preventing and treating thrombocytopenia Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient. ... | 09/11/2007 |
| 7169573 | Method for monitoring coagulability and hypercoagulable states The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particula... | 01/30/2007 |
| 7125841 | Mutant human factor IX with an increased resistance to inhibition by heparin The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this compositio... | 10/24/2006 |
| 7041635 | Factor VIII polypeptide The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared... | 05/09/2006 |
| 7033994 | Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet co... | 04/25/2006 |
| 7015193 | Compositions and methods to control bleeding Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation ... | 03/21/2006 |
| 7005454 | Polymeric drug formulations Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug ... | 02/28/2006 |
| 7005502 | Pharmaceutical preparation comprising vWF propeptide Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion. ... | 02/28/2006 |
| 6967239 | Method of filtering viruses from a factor VIII solution Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filterin... | 11/22/2005 |
| 6956022 | Agents for preventing and treating thrombocytopenia Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient. ... | 10/18/2005 |
| 6930087 | Pharmaceutical composition comprising factor VIII and neutral liposomes A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivat... | 08/16/2005 |
| 6903069 | Factor VII glycoforms The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII... | 06/07/2005 |
| 6884616 | DNA-construct for the tissue-specific expression of a blood coagulation factor A DNA-construct has been disclosed which is suitable for a tissue-specific expression of a blood coagulation factor like Factor IX, which comprises a DNA coding for an amino acid sequence of a blood coagulation factor and a DNA coding for a promoter which is specifi... | 04/26/2005 |
| 6866860 | Cationic alkyd polyesters for medical applications The present invention is directed to medical devices or pharmaceutical composition, each containing a synthetic, biodegradable, biocompatible polymer that is the reaction product of a polybasic acid or derivative thereof, a monoglyceride, and a cationic polyol. ... | 03/15/2005 |
| 6846484 | DTAT fusion toxin The invention provides fusion toxins that contain one or more regions of diphtheria toxin and a portion of urokinase-type plasminogen activator, as well as the nucleic acids that encode the fusion toxins and methods of using the fusion toxins. ... | 01/25/2005 |
| 6841371 | Protein C derivatives Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivati... | 01/11/2005 |
| 6833352 | Coagulation factor Viia composition The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream ... | 12/21/2004 |
| 6806063 | Factor VII or VIIa-like molecules Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa co... | 10/19/2004 |
| 6780614 | Modified factor VIII cDNA and its use for the production of factor VIII A modified Factor VIII cDNA is disclosed wherein the B-domain of the wild type factor cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in two locations of the Factor VIII cDNA and as a promoter a cDNA is used which is suitable for the expre... | 08/24/2004 |
| 6770744 | Modified factor VIII Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the speci... | 08/03/2004 |
| 6710083 | Method of treating palmar and plantar fibromatosis A method of treating palmar and plantar fibromatosis is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic acid. Preferably, the treatment method includes administering to a pat... | 03/23/2004 |
| 6593294 | Pharmaceutical composition comprising Factor VIII and neutral liposomes A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic li... | 07/15/2003 |
| 6576249 | Bone putty and method A method for the preparation of bone gel and bone putty which comprises producing a viscous supernatant by dissolving demineralized bone matrix in water or a solution comprising water and at least one component normally found in human blood serum, at a te... | 06/10/2003 |
| 6562374 | Biodegradable porous polymer scaffolds for tissue engineering prepared from an effervescent mixture and its preparation The present invention provides a method for preparing biodegradable porous polymer scaffolds for tissue engineering, comprising: a) fabricating a polymer sample from a polymer solution containing at least one biodegradable polymer and an effervescent mixture; ... | 05/13/2003 |
| 6548080 | Method for partially demineralized cortical bone constructs The invention is directed toward a sterile bone structure for application to a bone defect site to promote new bone growth at the site comprising a partially demineralized cortical bone structure, said bone structure comprising a cross sectional surface a... | 04/15/2003 |
| 6500427 | One-component tissue adhesive and a process for the production thereof A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof.... | 12/31/2002 |
| 6489296 | Method of reducing mortality in severe sepsis A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surger... | 12/03/2002 |
| 6458563 | Modified factor VIII The invention relates to a modified B-domainless form of porcine factor VIII, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.... | 10/01/2002 |
| 6423334 | Composition and method for enhancing transport across gastrointestinal tract cell layers A composition for enteral administration having a non-ionic vegetable oil GIT absorption enhancer capable of increasing the enteral absorbability of drugs, especially oral absorbability of hydrophilic and macromolecular drugs. The non-ionic vegetable oil ... | 07/23/2002 |
| 6403556 | Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.... | 06/11/2002 |
| 6387391 | Bioresorbable polymeric clayey and sticky substance This invention provides a claycy and sticky substance as a new biomaterial that cannot be found in the current medical field, which is bioresorbable, shows tackiness, plasticity and shape holding ability at a temperature of approximately from 30 to 40° C... | 05/14/2002 |
| 6346277 | Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X The present invention relates to a process for the preparation of a product of blood coagulation factors II, VII, IX and X which is virtually free of virus, the process comprising heating an aqueous liquid containing these factors in the presence of calci... | 02/12/2002 |
| 6346513 | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occ... | 02/12/2002 |
| 6268344 | Methods for treating hypercoagulable states or acquired protein C deficiency A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surger... | 07/31/2001 |
| 6218357 | Fibroin fluid and process for the production thereof A fibroin fluid obtained by adding carbon dioxide to a fibroin aqueous solution and then completely removing the carbon dioxide by pressure reduction or heating has fibroin microstructures which are dispersed in a dispersing medium, the fibroin fluid, unl... | 04/17/2001 |
| 6183743 | Modified factor VII The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to no... | 02/06/2001 |
| 6174855 | Pharmaceutical compositions comprising thrombin inhibitors and their use in the control of wound healing processes There is provided the use of a thrombin inhibitor in the manufacture of a product for use in the control of wound healing processes within the body, in particular, the inhibition or prevention of fibrin-related adhesion and/or scar tissue formation, as we... | 01/16/2001 |
| 6168788 | Fibrin glue without fibrinogen and biosealant compositions and methods The invention is a fibrin glue that avoids the use of fibrinogen and thus eliminates the need for premixing and premature clot formation. The fibrin glue of the invention comprises thrombin, thromboplastin and calcium and may have clotting Factors, VII, I... | 01/02/2001 |
| 6168789 | Modified factor VII The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions... | 01/02/2001 |
| 6156734 | Methods for treating hypercoagulable states or acquired protein C deficiency A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surger... | 12/05/2000 |
